Payment overview · 2025
General Payments
$389.02
18 reported records · 8 companies
Healthcare provider profile · identity verified
John W Wassenaar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OSPREY, FL · NPI 1669462297
Verified facts
What the public records show
CMS Open Payments records show John W Wassenaar, MD received $389.02 in general payments during 2025 across 18 reported records.
Exact Sciences Corporation accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.77 | 23.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.74 | 17.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.28 | 15.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.20 | 12.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.93 | 11.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.57 | 7.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.89 | 7.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.64 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $389.02 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $64.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.70 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 295 | 65 |
| Losartan Potassium | Losartan Potassium | 283 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 73 |
| Omeprazole | Omeprazole | 260 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 44 |
| Lisinopril | Lisinopril | 135 | 35 |
| Meloxicam | Meloxicam | 133 | 44 |
| Simvastatin | Simvastatin | 132 | 37 |
| Tramadol Hcl | Tramadol Hcl | 123 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 35 |
| Eliquis | Apixaban | 98 | 14 |
| Metformin Hcl | Metformin Hcl | 91 | 27 |
| Valsartan | Valsartan | 88 | 26 |
| Gabapentin | Gabapentin | 85 | 24 |
| Trazodone Hcl | Trazodone Hcl | 85 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 16 |
| Glipizide Er | Glipizide | 75 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 69 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 23 |
| Temazepam | Temazepam | 68 | 16 |
| Lorazepam | Lorazepam | 67 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Potassium Chloride | Potassium Chloride | 62 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 18 |
| Allopurinol | Allopurinol | 61 | 17 |
| Prednisone | Prednisone | 59 | 41 |
| Famotidine | Famotidine | 54 | 13 |
| Furosemide | Furosemide | 54 | 17 |
| Celecoxib | Celecoxib | 51 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 19 |
| Metformin Hcl Er | Metformin Hcl | 46 | 16 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 22 |
| Irbesartan | Irbesartan | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Etodolac | Etodolac | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 35 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Nifedipine Er | Nifedipine | 33 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $389.02 · 18 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, GARDASIL 9, GEMTESA, LEQVIO, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error